|
Memantine
|
No memantine
|
All
| |
---|
Placebo
|
Galantamine
|
Placebo
|
Galantamine
|
Memantine
|
No memantine
|
p value
|
---|
N
|
245
|
251
|
776
|
773
|
496
|
1549
| |
Sex
|
Women (%)
|
60.4
|
67.3
|
65.2
|
64.9
|
63.9
|
65.1
|
0.7976χ
|
Age (years)
|
Mean (SD)
|
74.2 (8.7)
|
73.8 (8.8)
|
72.8 (8.6)
|
72.7 (8.9)
|
74.0 (8.76)
|
72.8 (8.76)
|
0.008t
|
MMSE
|
Mean (SD)
|
18.4 (4.2)
|
18.0 (4.1)
|
19.1 (4.0)
|
19.4 (4.1)
|
18.2 (4.16)
|
19.2 (4.02)
|
0.0001t
|
DAD
|
Mean (SD)
|
59.0 (23.3)
|
57.0 (23.7)
|
61.5 (20.3)
|
63.4 (20.7)
|
58.0 (23.49)
|
62.5 (20.52)
|
0.0001t
|
AD duration (years)
|
Mean (SD)
|
0.8 (1.3)
|
1.1 (1.7)
|
0.8 (1.7)
|
0.7 (1.3)
|
0.95 (1.50)
|
0.75 (1.57)
|
0.0127t
|
Prior therapy
|
Cholinomimetic use (%)
|
23.3
|
23.5
|
16.0
|
13.3
|
23.4
|
14.7
|
0.0001χ
|
Nursing home placement
|
N
|
116
|
101
|
312
|
305
|
217
|
617
| |
Cases, n (%)
|
10 (8.6)
|
3 (3.0)
|
14 (4.5)
|
13 (4.3)
|
13 (6.0)
|
27 (4.4)
|
0.3507χ
|
-
χChi-square analysis
-
t
t test
-
AD Alzheimer’s disease, DAD disability assessment for dementia, MMSE mini–mental state examination, SD standard deviation